Analyst Judah Frommer of Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), retaining the price target of $111.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Judah Frommer has given his Buy rating due to a combination of factors including the promising developments in Arcellx Inc’s iMMagine-1 trial and the company’s financial outlook. The upcoming presentation at the European Hematology Association (EHA) on June 14 is expected to provide significant updates on the iMMagine-1 trial, which targets relapsed/refractory multiple myeloma. The absence of delayed neurotoxicity in patients is seen as a positive indicator, and the differentiated safety profile of their CAR-T therapy, anito-cel, is noteworthy.
Additionally, Arcellx’s financial position is strong, with a cash runway expected to fund operations into 2028. The company plans to commercially launch anito-cel in 2026, and the addition of MRD negativity as a dual primary endpoint in their iMMagine-3 trial further supports the potential for positive outcomes. Despite recent share price pullbacks amid FDA uncertainties, these developments present a greater opportunity for the company, reinforcing the Buy rating.